Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
183490.KQ
STRONG SELLEnzychem Lifesciences Corporation · Healthcare · South Korea · $55M · Avg Vol: $0/d
18
StockRankQ
39
V
45
M
24
P/E (TTM)
—
ROE
-13.2%
D/E
0.0x
Dividend %
—
COMPANY DESCRIPTION
Enzychem Lifesciences Corporation engages in developing novel small molecule therapeutics for patients with unmet needs for oncology, inflammatory, and severe respiratory diseases in South Korea.
FINANCIAL SUMMARY (USD)
| Year | 2021 | 2022 | 2023 | 2024 | 2025 | CAGR |
|---|---|---|---|---|---|---|
| Revenue | — | 18M | 50M | 51M | 45M | 36.5% |
| EPS | — | -0.21 | -0.07 | -0.18 | -0.15 | — |
| Shares | — | 84M | 85M | 85M | 85M | +0.9% |
| Debt | 2M | 25M | 4M | 3M | 3M | 11.1% |
| Equity | — | 133M | 127M | 106M | 91M | -12.0% |
| Op CF | — | -9M | -7M | -377,793 | -7M | — |
| Inv CF | — | -72M | 35M | 5M | 8M | — |
| Fin CF | — | 85M | -23M | -8M | -2M | — |
Loading...
PRICE (1M)+0.0%
SMA 50SMA 200
Close
$0.65
52W High
$1.16
From 52W High
0.6%
SCORE BREAKDOWN
Quality
39
ROIC
-12.9%32.3
ROE
-13.2%33.4
GP/Assets
2.9%15.5
Op. Margin
-18.1%26.6
FCF/Assets
-7.9%30.9
Piotroski
—28.7
Int. Cover
-50.0x6.4
D/E Ratio
0.04x76.4
Current Ratio
6.55x78.6
Value
45
P/E (TTM)
—N/A
EV/EBITDA
2.4x60.8
P/FCF
—N/A
P/B
0.6x88.2
P/S
3.0x57.0
Div Yield
—N/A
Momentum
24
52W High %
56%33.0
RS 6M
-120%7.3
SMA 50/200
0.89x30.7
EPS Rev 4W
—N/A
EPS Rev 12W
—N/A
EPS Improve
—N/A
Q Growth
—N/A
FUNDAMENTALS
Market Cap
$55M
P/E (Forward)
—
Gross Margin
15.3%
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of 183490.KQ are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| 183490.KQ | Enzychem Lifesciences Corporation(you) | $55M | 18 | STRONG SELL |
| 063160.KS | CKD Bio Corp. | $62M | 15 | STRONG SELL |
| 002390.KS | HANDOK Inc. | $73M | 17 | STRONG SELL |
| 032300.KQ | KOREA PHARMA Co., Ltd. | $63M | 12 | STRONG SELL |
| 092040.KQ | Amicogen, Inc. | $58M | 7 | STRONG SELL |
| 000520.KS | Samil Pharmaceutical Co.,Ltd | $105M | 14 | STRONG SELL |
| 058820.KQ | CMG Pharmaceutical Co., Ltd. | $107M | 14 | STRONG SELL |
| 256840.KQ | BNC KOREA, Inc. | $131M | 19 | STRONG SELL |
| 214390.KS | Kyongbo Pharmaceutical Co., Ltd | $91M | 27 | SELL |
| 004310.KS | Hyundai Pharmaceutical Co., Ltd. | $117M | 23 | SELL |
Peer medians: ROE -1.1% · P/E 17.7x · Gross margin 43.6%